A Double-Blind, Placebo-Controlled Evaluation of the Effect of Oral Doses of Rizatriptan 10 mg on Oral Contraceptive Pharmacokinetics in Healthy Female Volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 3, 2000, Pages 309-315

  Shadle, Craig R ^a   Liu, Guanghan ^b   Goldberg, Michael R ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HTR1B PROTEIN, HUMAN; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TRIAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; FEMALE; HUMANS; MESTRANOL; NORETHINDRONE; PLACEBOS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 0034145688     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008865     Document Type: Article

References (11)

1. Beer M, Middlemiss D, Stanton J, Longmore J, Hargreaves R, Noble A, Scholey K, Bevan Y, Hill R, Baker R, Street L, Matassa V, Iversen L: In vitro pharmacological profile of the novel 5-HT1D receptor agonist, MK-462. Cephalagia 1995;15:203P.
2. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group: Rizatriptan vs sumatriptan in the acute treatment of migraine. Arch Neurol Chicago 1996;53(11):1132-1137.
3. Kramer MS, Matzura-Wolfe D, Getson A, Polis A, Reines SA, and the Rizatriptan Multiple Attack Study Group: Placebo-controlled, double-blind study of rizatriptan in multiple attacks of acute migraine. Neurology 1997;43(Suppl. 2):A68-A69.
4. Block GA, Smith M, Jiang K, Reines S, Teall J, and the Rizatriptan 022 Study Group: Rizatriptan (MK-0462) for the acute treatment of migraine and migraine recurrence. Neurology 1997;48(3, Suppl. 2):A68.
5. Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T: Initial human experience with MK-462 (rizatriptan): a novel 5-HT-1D agonst. Br J Clin Pharmacol 1997;43(1):49-54.
6. Cheng HC, Polvino WJ, Sciberras D, Yogendran L, Cerchio KA, Christie K, Olah TV, McLoughlin D, James I, Rogers JD: Pharmacokinetics and food interaction of MK-462 in healthy males. Biopharm Drug Dispos 1996;17:17-24.
7. Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. J Am Med Assoc 1992;267:64-69.
8. Lee G, et al: Determination of ethinylestradiol and norethindrone in a single specimen of plasma by automated high-performance liquid chromatography and subsequent radioimmunoassay. J Liquid Chrsmat 1987;10:2305-2318.
9. ] Immunoradiometric Assay Kit, Orion Diagnostica, Finland. Kit insert dated May 1994.
10. Lee Y, Ermlich SJ, Sterrett AT, Goldberg MR, Blum RA, Brucker MJ, McLoughlin DA, Olah TV, Zhao J, Rogers JD: Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. Biopharm Drug Dispos 1998;19:577-581.
11. Lee Y, Conroy JA, Stepanavage ME, Mendel CM, Somers G, McLoughlin DA, Olah TV, De Smet M, Keymeulen B, Rogers JD: Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 1999;47:373-378.